Glucose Laboratoire Aguettant

Glucose Laboratoire Aguettant is an intravenous solution that contains glucose monohydrate as its active ingredient. The product is supplied in a sterile liquid form for parenteral administration, with the specific concentration not disclosed in the public data. Marketed in the European Union and available by prescription only, it is classified as an excipient/solvent used to provide an energy source during intravenous therapy in clinical settings.

Glucose Laboratoire Aguettant is employed in several clinical situations where rapid provision of carbohydrate calories and fluid balance is required to restore homeostasis and provide caloric support.

- Fluid and electrolyte replacement in patients unable to take oral intake. - Treatment of hypoglycemia when blood glucose levels are critically low. - Component of parenteral nutrition regimens for patients receiving total nutrient support. - Support during peri‑operative care to maintain energy supply. - Management of metabolic demands in critically ill or trauma patients. - Correction of osmotic diuresis associated with hyperglycemic states.

When administered intravenously, Glucose Laboratoire Aguettant may be associated with a range of observed effects, most of which are related to its osmotic and metabolic properties.

Common: - Transient hyperglycemia that resolves as glucose is metabolized. - Mild electrolyte shifts, particularly sodium and potassium fluctuations. - Local irritation at the infusion site, such as redness or mild pain. - Fluid overload in patients with compromised cardiac or renal function. - Mild increase in serum osmolality that normalizes after infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Significant electrolyte imbalances causing cardiac arrhythmias. - Hypersensitivity reactions, including rash, itching, or anaphylaxis. - Pulmonary edema in patients receiving large volumes rapidly. - Severe fluid overload resulting in congestive heart failure exacerbation.

Prior to using Glucose Laboratoire Aguettant, clinicians should evaluate patient-specific factors and monitor parameters that may influence safety and effectiveness.

- Assess blood glucose levels and adjust infusion rates to avoid hyperglycemia. - Evaluate renal and cardiac function, especially in patients at risk for fluid overload. - Monitor serum electrolytes, particularly sodium, potassium, and phosphate, during and after administration. - Use caution in patients with known hypersensitivity to glucose solutions or related excipients. - Avoid rapid infusion of large volumes unless clinically justified. - Consider compatibility with other intravenous medications to prevent precipitation. - Document infusion volume and rate in the patient’s medical record.

Glucose Laboratoire Aguettant may interact with other intravenous agents or systemic medications, influencing glucose metabolism, electrolyte balance, or solution compatibility.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring. - Simultaneous infusion of calcium-containing solutions that can precipitate with phosphate in the glucose solution.

Use with caution: - Concurrent use of diuretics that may exacerbate electrolyte shifts. - Administration alongside beta‑adrenergic agonists, which can increase glucose production. - Use with other hyperosmolar solutions, requiring careful monitoring of serum osmolality. - Combination with blood transfusions, as rapid volume changes may affect fluid balance.